Please ensure Javascript is enabled for purposes of website accessibility

Why NeuBase Therapeutics Popped by 16.5% on Friday

By Eric Volkman - Updated Jan 22, 2021 at 7:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of its investors praised the company in a quarterly performance update.

What happened

NeuBase Therapeutics (NBSE -1.94%) ended the week on a real sugar high, rising by nearly 17% on Friday. This was due to a glowing note about the biotech from one of its more prominent investors.

So what

The praise came from Greenlight Capital, the hedge fund run by noted investor David Einhorn. On Thursday, Greenlight released the latest quarterly update on its performance.

As is its habit, Greenlight dived into the particulars of several portfolio investments, among which was NeuBase. Greenlight waxed enthusiastic about the company's PATrOL platform, a cutting-edge technology which modifies the protein function of genes in order to precisely target diseases.

A medical professional using a microscope

Image source: Getty Images.

"By addressing all of the causal mechanisms underlying rare and common diseases –- including cancer –- PATrOL consolidates the capabilities of highly valued gene silencing, gene editing and gene replacement companies in a single unified platform," Greenlight wrote in its assessment.

Describing the risk-reward proportion of NeuBase as "asymmetrical," Greenlight believes PATrOL has the potential to be a game-changing technology that could help fight a wide range of afflictions.

Now what

Greenlight is a true believer in that potential; it originally began loading up on NeuBase stock in the third quarter of 2019, and has since added several times to its holdings.

While the hedge fund manager's assessment of the company's prospects is believable, we should bear in mind that NeuBase is still a preclinical-stage biotech with no products on the market, and thus carries a very high degree of risk as an investment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NeuBase Therapeutics, Inc. Stock Quote
NeuBase Therapeutics, Inc.
$1.01 (-1.94%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.